Exelixis | EXEL - Current Liabilities


Exelixis reported $373.78M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 356.58M 26.56M Sep/2025
Agios Pharmaceuticals USD 74.76M 4.35M Sep/2025
Amgen USD 21.79B 1.32B Sep/2025
AstraZeneca USD 34.05B 518M Sep/2025
Bayer EUR 28.96B 825M Sep/2025
BioMarin Pharmaceutical USD 798.44M 114.19M Sep/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Cytokinetics USD 142.14M 11.08M Sep/2025
Eisai JPY 378.25B 33.36B Sep/2025
Eli Lilly USD 40.14B 1.12B Sep/2025
Exelixis USD 373.78M 37.67M Sep/2025
Genmab DKK 629M 127M Jun/2025
Glaxosmithkline GBP 28.68B 8.3B Sep/2025
Incyte USD 1.34B 60.11M Sep/2025
Ionis Pharmaceuticals USD 903.46M 6.22M Sep/2025
MacroGenics USD 44.47M 5.47M Sep/2025
Merck USD 28.63B 2.59B Sep/2025
Moderna USD 1.68B 109M Sep/2025
Neurocrine Biosciences USD 638M 91.7M Sep/2025
Novartis USD 32B 286M Sep/2025
Pfizer USD 36.6B 1.13B Sep/2025
Sanofi EUR 28.35B 9.32B Dec/2025
Takeda JPY 2.61T 470.53B Dec/2025
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
Xencor USD 86.48M 9.6M Sep/2025